MAP
ORKA

Moody Aldrich Partners’s Oruka Therapeutics ORKA Stock Holding History

Moody Aldrich Partners’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.65M Sell
101,411
-33,650
-25% -$2.24M 1.73% 2
2026
Q1 		$6.62M Buy
135,061
+8,249
+7% +$287K 1.19% 17
2025
Q4 		$3.84M Buy
+126,812
New +$3.53M 0.72% 61

Other funds holding ORKA

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
SAM
Secure Asset Management Troy, Michigan $714M AUM 27.91% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
GI
Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
AFC
Ares Financial Consulting Calabasas, California $139M AUM

Moody Aldrich Partners's ORKA Position: Q2 2026 in Review

Moody Aldrich Partners reduced its Oruka Therapeutics (ORKA) stake by 25% in Q2 2026, selling an estimated $2.24M and leaving 101,411 shares worth $9.65M. The position accounts for 1.73% of the portfolio, ranked #2.

Moody Aldrich Partners first reported a position in ORKA in Q4 2025 and has held it in 3 quarters since. 12 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Moody Aldrich Partners held 101,411 shares of Oruka Therapeutics worth $9.65M as of Q2 2026.
  • Moody Aldrich Partners sold 33,650 Oruka Therapeutics shares in Q2 2026, an estimated $2.24M.
  • Oruka Therapeutics made up 1.73% of Moody Aldrich Partners's portfolio in Q2 2026, its #2 holding.
  • Moody Aldrich Partners first reported a position in Oruka Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 12 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.